1. Tailoring CDK4/6 Inhibitor Therapy for Advanced Breast Cancer

3. CDK4/6 Inhibitors — A New Standard of Care in HR+/HER2− Metastatic Breast Cancer

4. All Showed PFS Benefit vs Single-Agent Endocrine Therapy

5. MONARCH 2 Abemaciclib + Fulvestrant in Progressive Disease

6. MONARCH 2 PFS and OS Outcomes

7. MONARCH 2 Median Overall Survival by Stratification Factors

8. MONARCH 2 Overall Survival by Metastatic Site

9. MONARCH 2 Overall Survival by Endocrine Therapy Resistance

10. MONARCH 2 Exploratory Analysis — Time to Chemotherapy

11. MONALEESA-3 Ribociclib + Fulvestrant in Progressive Disease

12. MONALEESA-3 PFS in Overall Population

13. MONALEESA-3 OS Results

14. MONALEESA-3 Median OS by Line of Therapy

15. PALOMA-3 Palbociclib + Fulvestrant in Progressive Disease

16. PALOMA-3 Key Outcomes

17. Implications of Data

18. MONARCH 3 First-Line Abemaciclib + AI in Postmenopausal Women

19. MONALEESA Trials First-Line Ribociclib + ET

20. MONALEESA-2 First-Line Ribociclib + ET in Postmenopausal Women

21. MONALEESA-7 First-Line Ribociclib + ET in Premenopausal Women

22. PALOMA-2 First-Line Palbociclib + Letrozole

23. PALOMA-2 Results

24. Using CDK4/6 Inhibitors

25. Tailoring Treatment With CDK4/6 Inhibitors

26. Unanswered Questions

27. Using CDK4/6 Inhibitors in Postmenopausal Patients

28. Toxicities of CDK4/6 Inhibitors

29. Managing CDK4/6 Inhibitor Toxicities

30. Interstitial Lung Disease

31. Ongoing Questions and Future Directions

32. PACE Study Design

33. Exploring Drivers of Resistance

34. Could CDK4/6 Inhibitors Have a Role in Early Breast Cancer?

35. Concluding Remarks

36. Abbreviations

37. Abbreviations (cont)